GMED · Company research
GLOBUS MEDICAL INC (GMED): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
80records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| GMED or AXGN: Which Is the Better Value Stock Right Now? | In a comparison of two medical instruments stocks, Globus Medical (GMED) and AxoGen (AXGN), both holding a Zacks Rank #2 (Buy), GMED emerges as the superior value option. GMED has a forward P/E of 15.81 compared to AXGN's 73.46, a PEG ratio of 1.27 vs 1.42, and a P/B ratio of 2.22 vs 7.47, earning GMED a Value grade of B while AXGN received an F. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | neutral | 0 | 1 |
| Reasons to Add STE Stock to Your Portfolio Right Now | STERIS (STE) reported Healthcare segment sales growth of 8% to $1.05 billion in fiscal Q1, driven by services and consumables, while AST segment grew 6% to $297.6 million with improved growth expected in H2. The company faces margin pressures from $14 million in tariff costs and inflation, though strong demand persists in healthcare and life sciences markets. Management maintains fiscal 2027 EPS guidance at $11.12 with projected 7.3% revenue growth. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.75 | 1 |
| Haemonetics Gains 149.3% in a Year: What's Driving the Rally? | Haemonetics shares surged 149.3% over the past year, significantly outperforming the industry and S&P 500. The company's Plasma and MedSurg segments showed solid growth in Q1 fiscal 2027, with Plasma revenues up 7.2% and MedSurg up 6%. HAE raised its fiscal 2027 revenue guidance to 5-8%, but faces headwinds from high debt levels ($1.17 billion long-term debt) and competitive pressures. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Reasons to Add STE Stock to Your Portfolio Right Now | STERIS (STE) reported Healthcare segment sales growth of 8% to $1.05 billion in fiscal Q1, driven by services and consumables, while AST segment grew 6% to $297.6 million with improved growth expected in H2. The company faces margin pressures from $14 million in tariff costs and inflation, though strong demand persists in healthcare and life sciences markets. Management maintains fiscal 2027 EPS guidance at $11.12 with projected 7.3% revenue growth. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.75 | 1 |
| Haemonetics Gains 149.3% in a Year: What's Driving the Rally? | Haemonetics shares surged 149.3% over the past year, significantly outperforming the industry and S&P 500. The company's Plasma and MedSurg segments showed solid growth in Q1 fiscal 2027, with Plasma revenues up 7.2% and MedSurg up 6%. HAE raised its fiscal 2027 revenue guidance to 5-8%, but faces headwinds from high debt levels ($1.17 billion long-term debt) and competitive pressures. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Is it Apt to Retain Medtronic Stock in Your Portfolio Now? | Medtronic is expanding its presence in high-growth markets including cardiac ablation (up 88%), robotics, and structural heart, while advancing the MiniMed separation. The company is building its hypertension business through the Symplicity Spyral renal denervation franchise with improved reimbursement and clinical evidence. However, Medtronic faces headwinds from tariffs, inflation, currency fluctuations, and unfavorable product mix that could pressure margins. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.75 | 1 |
| Is it Apt to Retain Medtronic Stock in Your Portfolio Now? | Medtronic is expanding its presence in high-growth markets including cardiac ablation (up 88%), robotics, and structural heart, while advancing the MiniMed separation. The company is building its hypertension business through the Symplicity Spyral renal denervation franchise with improved reimbursement and clinical evidence. However, Medtronic faces headwinds from tariffs, inflation, currency fluctuations, and unfavorable product mix that could pressure margins. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.75 | 1 |
| BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients | Becton, Dickinson and Company (BD) announced positive nine-month results from the AGILITY trial for its Revello Vascular Covered Stent in treating iliac artery disease. The trial met its primary endpoint with a 2.8% failure rate, 97.2% primary patency, and 98.3% freedom from clinically driven target lesion revascularization. The device remains investigational in the U.S. with clinical follow-up continuing through 36 months. The global iliac stent market is projected to grow at a 6.5% CAGR through 2033. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients | Becton, Dickinson and Company (BD) announced positive nine-month results from the AGILITY trial for its Revello Vascular Covered Stent in treating iliac artery disease. The trial met its primary endpoint with a 2.8% failure rate, 97.2% primary patency, and 98.3% freedom from clinically driven target lesion revascularization. The device remains investigational in the U.S. with clinical follow-up continuing through 36 months. The global iliac stent market is projected to grow at a 6.5% CAGR through 2033. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| Doximity Deepens U.S. News Alliance to Improve Patient Access to Care | Doximity announced an extension of its 13-year partnership with U.S. News & World Report, continuing to provide physician data for Doctor Finder, Patient Connect appointment-booking tools, and Expert Opinion surveys for hospital rankings. The partnership leverages Doximity's network of 3+ million medical professionals to connect patients with healthcare providers. Despite the news, DOCS stock declined 2.1% following the announcement and is down 32.4% year-to-date. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.75 | 1 |
| Doximity Deepens U.S. News Alliance to Improve Patient Access to Care | Doximity announced an extension of its 13-year partnership with U.S. News & World Report, continuing to provide physician data for Doctor Finder, Patient Connect appointment-booking tools, and Expert Opinion surveys for hospital rankings. The partnership leverages Doximity's network of 3+ million medical professionals to connect patients with healthcare providers. Despite the news, DOCS stock declined 2.1% following the announcement and is down 32.4% year-to-date. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.75 | 1 |
| Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now? | Prestige Consumer Healthcare (PBH) is building its consumer health brand portfolio through strategic acquisitions of Breathe Right and LaCorium, expected to contribute $190 million in fiscal 2027 revenues. The company benefits from strong e-commerce growth at double-digit rates and brand-building initiatives across established franchises. However, intense competition, pricing pressure, and foreign exchange fluctuations pose ongoing challenges. PBH holds a Zacks Rank #3 (Hold) rating with an earnings yield of 9.4%, outpacing the industry average. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.75 | 1 |
| Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now? | Prestige Consumer Healthcare (PBH) is building its consumer health brand portfolio through strategic acquisitions of Breathe Right and LaCorium, expected to contribute $190 million in fiscal 2027 revenues. The company benefits from strong e-commerce growth at double-digit rates and brand-building initiatives across established franchises. However, intense competition, pricing pressure, and foreign exchange fluctuations pose ongoing challenges. PBH holds a Zacks Rank #3 (Hold) rating with an earnings yield of 9.4%, outpacing the industry average. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.75 | 1 |
| Is Globus Medical (GMED) Cheap On Its Spine Platform Reveal? - Yahoo Finance | Is Globus Medical (GMED) Cheap On Its Spine Platform Reveal? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| What Does Globus Medical (GMED) Mean For Spine Care After Its NASS 2026 Reveal? - Yahoo Finance | What Does Globus Medical (GMED) Mean For Spine Care After Its NASS 2026 Reveal? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| Globus Medical (GMED) Stock Looks Discounted Against Its Earnings Outlook - Yahoo Finance | Globus Medical (GMED) Stock Looks Discounted Against Its Earnings Outlook Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? | Glaukos Corporation (GKOS) shares have gained 36.8% over six months, outperforming its industry, driven by strong Q2 results with 50% revenue growth to $185.6 million, successful commercial expansion of Epioxa for keratoconus treatment, positive clinical data for iDose TR, and pipeline advances including a new retinal disease licensing agreement. The company raised its 2026 revenue guidance to $680-$700 million. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Globus Medical, Inc. (GMED.MX) stock price, news, quote and history - Yahoo Finance UK | Globus Medical, Inc. (GMED.MX) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 14, 2026 | neutral | 0 | 0.6 |
| BTSG Stock Climbs 67.3% YTD: What's Driving the Rally in 2026? | BrightSpring Health Services (BTSG) has surged 67.3% year-to-date, outperforming broader markets, driven by strong growth in Specialty and Infusion revenues (up 32.7%) and Provider Services (up 29.1%). The company raised its 2026 outlook twice and improved leverage to 2.15x after divesting its Community Living business. However, a $200M IRA impact on Home and Community Pharmacy and integration execution risks present headwinds. Analysts rate BTSG as a Hold. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| BTSG Stock Climbs 67.3% YTD: What's Driving the Rally in 2026? | BrightSpring Health Services (BTSG) has surged 67.3% year-to-date, outperforming broader markets, driven by strong growth in Specialty and Infusion revenues (up 32.7%) and Provider Services (up 29.1%). The company raised its 2026 outlook twice and improved leverage to 2.15x after divesting its Community Living business. However, a $200M IRA impact on Home and Community Pharmacy and integration execution risks present headwinds. Analysts rate BTSG as a Hold. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Reasons to Add QuidelOrtho Stock to Your Portfolio for Now | QuidelOrtho Corporation (QDEL) shows strong Q2 2026 results with 21% adjusted EBITDA growth and expanding margins, supported by a diversified product portfolio and $50 million cost-saving initiatives through 2027. However, weak respiratory demand and overdependence on this segment pose risks, with the company adopting a cautious outlook for the 2026-2027 respiratory season. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Reasons to Add QuidelOrtho Stock to Your Portfolio for Now | QuidelOrtho Corporation (QDEL) shows strong Q2 2026 results with 21% adjusted EBITDA growth and expanding margins, supported by a diversified product portfolio and $50 million cost-saving initiatives through 2027. However, weak respiratory demand and overdependence on this segment pose risks, with the company adopting a cautious outlook for the 2026-2027 respiratory season. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Hims & Hers Expands Australian Women's Health Platform With Hers | Hims & Hers Health has launched Hers, its women's health platform, in Australia by rebranding Juniper from its Eucalyptus acquisition. The platform offers personalized care for hair regrowth, menopause, and weight management with 24/7 support. The expansion leverages Eucalyptus' local presence to strengthen brand recognition and recurring revenue in the growing Australian telehealth market, which is projected to grow at 18.2% CAGR through 2034. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.75 | 1 |
| Hims & Hers Expands Australian Women's Health Platform With Hers | Hims & Hers Health has launched Hers, its women's health platform, in Australia by rebranding Juniper from its Eucalyptus acquisition. The platform offers personalized care for hair regrowth, menopause, and weight management with 24/7 support. The expansion leverages Eucalyptus' local presence to strengthen brand recognition and recurring revenue in the growing Australian telehealth market, which is projected to grow at 18.2% CAGR through 2034. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.75 | 1 |
| A new platform is designed to let surgeons tailor spinal implants to each patient. Globus Medical will preview it at NASS. - Stock Titan | A new platform is designed to let surgeons tailor spinal implants to each patient. Globus Medical will preview it at NASS. Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| Here's Why You Should Retain DexCom Stock in Your Portfolio for Now | DexCom (DXCM) reported strong Q2 2026 results with gross margin expanding to 64.1% and operating margin at 25.1%, driven by manufacturing efficiencies and G7 15-day product transition. However, near-term profitability could face pressure from Ireland factory ramp-up costs, forex headwinds, and higher oil-linked input costs. The company maintains a Zacks Rank #3 (Hold) rating with shares up 29.4% year-to-date. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.75 | 1 |
| Here's Why You Should Retain DexCom Stock in Your Portfolio for Now | DexCom (DXCM) reported strong Q2 2026 results with gross margin expanding to 64.1% and operating margin at 25.1%, driven by manufacturing efficiencies and G7 15-day product transition. However, near-term profitability could face pressure from Ireland factory ramp-up costs, forex headwinds, and higher oil-linked input costs. The company maintains a Zacks Rank #3 (Hold) rating with shares up 29.4% year-to-date. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.75 | 1 |
| ISRG Is Expanding Beyond Surgery: Here's Why the GI Opportunity Matters | Intuitive Surgical submitted a next-generation flexible robotic endoscope to the FDA for 510(k) clearance, marking expansion into gastrointestinal care. The platform combines expertise from da Vinci surgical systems and Ion lung biopsy platform but remains in early development with no near-term revenue expected. Success will depend on regulatory approval, clinical evidence, and physician adoption. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| ISRG Is Expanding Beyond Surgery: Here's Why the GI Opportunity Matters | Intuitive Surgical submitted a next-generation flexible robotic endoscope to the FDA for 510(k) clearance, marking expansion into gastrointestinal care. The platform combines expertise from da Vinci surgical systems and Ion lung biopsy platform but remains in early development with no near-term revenue expected. Success will depend on regulatory approval, clinical evidence, and physician adoption. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Here's Why You Should Add Avantor Stock to Your Portfolio for Now | Avantor (AVTR) reported strong second-quarter 2026 results with raised 2026 guidance, driven by VWR segment's return to 1.7% organic growth and BMP's double-digit order growth. However, BMP's continued 5.6% organic revenue decline and uneven demand recovery remain concerns. The company's Revival program shows execution improvements across commercial performance and operations. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Here's Why You Should Add Avantor Stock to Your Portfolio for Now | Avantor (AVTR) reported strong second-quarter 2026 results with raised 2026 guidance, driven by VWR segment's return to 1.7% organic growth and BMP's double-digit order growth. However, BMP's continued 5.6% organic revenue decline and uneven demand recovery remain concerns. The company's Revival program shows execution improvements across commercial performance and operations. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms | Veeva Systems announced that over 175 emerging biotech companies are adopting Veeva Basics to streamline drug development operations. The pre-configured platform helps smaller biotechs establish technology infrastructure for clinical, regulatory, and quality processes. Growing adoption could support long-term revenue growth as these companies expand, though financial impact depends on customer retention and conversion to meaningful revenue. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms | Veeva Systems announced that over 175 emerging biotech companies are adopting Veeva Basics to streamline drug development operations. The pre-configured platform helps smaller biotechs establish technology infrastructure for clinical, regulatory, and quality processes. Growing adoption could support long-term revenue growth as these companies expand, though financial impact depends on customer retention and conversion to meaningful revenue. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Here's Why You Should Retain AMN Stock in Your Portfolio for Now | AMN Healthcare is positioned for growth driven by rising healthcare staffing demand, technology investments, and higher-margin services, with Nurse and Allied revenues up 11% and Passport users growing 33%. However, persistent pricing competition, weakness in physician and technology segments, and earnings normalization pose significant headwinds to sustained performance. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 0.75 | 1 |
| ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y | AngioDynamics (ANGO) reported Q1 FY2027 adjusted loss of 4 cents per share, beating estimates by 60%, with revenues up 6.9% to $80.9 million. Med Tech revenues grew 13.2%, driven by strong performance from Auryon, AlphaVac, and NanoKnife. Gross margin expanded 410 basis points to 59.4%, though the stock fell over 20% following the announcement. The company reiterated FY2027 guidance of $336-$341 million in revenues with Med Tech expected to grow 12-15%. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.75 | 1 |
| ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y | AngioDynamics (ANGO) reported Q1 FY2027 adjusted loss of 4 cents per share, beating estimates by 60%, with revenues up 6.9% to $80.9 million. Med Tech revenues grew 13.2%, driven by strong performance from Auryon, AlphaVac, and NanoKnife. Gross margin expanded 410 basis points to 59.4%, though the stock fell over 20% following the announcement. The company reiterated FY2027 guidance of $336-$341 million in revenues with Med Tech expected to grow 12-15%. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.75 | 1 |
| Reasons to Hold Veeva Systems Stock in Your Portfolio for Now | Veeva Systems (VEEV) delivered strong Q2 fiscal 2027 results, beating estimates and raising its full-year outlook, driven by expanding Vault CRM adoption with 12 of top 20 biopharmas committed and over 180 customers live. The company is advancing AI initiatives with Veeva Falcon attracting early adopters. However, market saturation in the life sciences CRM space and intensifying competition from traditional and AI-powered platforms could constrain future growth rates. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.75 | 1 |
| Reasons to Hold Veeva Systems Stock in Your Portfolio for Now | Veeva Systems (VEEV) delivered strong Q2 fiscal 2027 results, beating estimates and raising its full-year outlook, driven by expanding Vault CRM adoption with 12 of top 20 biopharmas committed and over 180 customers live. The company is advancing AI initiatives with Veeva Falcon attracting early adopters. However, market saturation in the life sciences CRM space and intensifying competition from traditional and AI-powered platforms could constrain future growth rates. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.75 | 1 |
| Is it the Right Time to Hold TNDM Stock in Your Portfolio? | Tandem Diabetes Care (TNDM) is expanding its product portfolio with new tubeless pump technology and next-generation closed-loop systems while driving international sales growth through direct commercialization. However, the company faces headwinds from intense competitive pressure, GLP-1 drug adoption impacts on insulin therapy demand, and supply chain constraints that are expected to persist through 2026. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.75 | 1 |
| Is it the Right Time to Hold TNDM Stock in Your Portfolio? | Tandem Diabetes Care (TNDM) is expanding its product portfolio with new tubeless pump technology and next-generation closed-loop systems while driving international sales growth through direct commercialization. However, the company faces headwinds from intense competitive pressure, GLP-1 drug adoption impacts on insulin therapy demand, and supply chain constraints that are expected to persist through 2026. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.75 | 1 |
| Here's Why You Should Retain DaVita Stock in Your Portfolio for Now | DaVita (DVA) has rallied 55.8% year-to-date, driven by strong Integrated Kidney Care (IKC) platform growth, improving treatment volumes, and technology investments. The company beat Q2 expectations by $40 million in adjusted operating income and raised full-year guidance. However, persistent headwinds include declining revenue per treatment due to commercial-mix pressure (estimated $70 million impact in 2027), elevated G&A costs limiting operating leverage, and limited acquisition opportunities in a consolidated market. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.25 | 1 |
| Here's Why You Should Retain DaVita Stock in Your Portfolio for Now | DaVita (DVA) has rallied 55.8% year-to-date, driven by strong Integrated Kidney Care (IKC) platform growth, improving treatment volumes, and technology investments. The company beat Q2 expectations by $40 million in adjusted operating income and raised full-year guidance. However, persistent headwinds include declining revenue per treatment due to commercial-mix pressure (estimated $70 million impact in 2027), elevated G&A costs limiting operating leverage, and limited acquisition opportunities in a consolidated market. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.25 | 1 |
| Globus Medical, Inc. (GMED) Stock forecasts - Yahoo Finance Singapore | Globus Medical, Inc. (GMED) Stock forecasts Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 9, 2026 | neutral | 0 | 0.6 |
| Is it the Right Time to Add Phibro Stock to Your Portfolio? | Phibro Animal Health (PAHC) is gaining momentum from strong Animal Health segment growth, driven by the Zoetis MFA acquisition, vaccine expansion, and mineral nutrition demand recovery. However, the company faces headwinds from macroeconomic risks, trade policy uncertainties, and foreign exchange volatility that continue to pressure reported results. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.6 | 1 |
| Is it the Right Time to Add Phibro Stock to Your Portfolio? | Phibro Animal Health (PAHC) is gaining momentum from strong Animal Health segment growth, driven by the Zoetis MFA acquisition, vaccine expansion, and mineral nutrition demand recovery. However, the company faces headwinds from macroeconomic risks, trade policy uncertainties, and foreign exchange volatility that continue to pressure reported results. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.6 | 1 |
| Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets | Smith+Nephew announced the European commercial launch of its CARTIHEAL AGILI-C Cartilage Repair Implant across 12 key markets, expanding its Sports Medicine portfolio. The product is backed by clinical evidence showing superior knee outcomes and pain relief over five years. The global cartilage repair market is projected to grow from $5.98 billion in 2024 to $8.04 billion by 2030 at a 5.1% CAGR. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets | Smith+Nephew announced the European commercial launch of its CARTIHEAL AGILI-C Cartilage Repair Implant across 12 key markets, expanding its Sports Medicine portfolio. The product is backed by clinical evidence showing superior knee outcomes and pain relief over five years. The global cartilage repair market is projected to grow from $5.98 billion in 2024 to $8.04 billion by 2030 at a 5.1% CAGR. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Reasons to Retain Hims & Hers Stock in Your Portfolio for Now | Hims & Hers (HIMS) is accelerating growth through weight loss offerings, international expansion, and AI-enabled care, with U.S. revenues up 16% and international revenues surging 17-fold. However, the company faces headwinds from gross margin compression due to lower-margin branded products, negative cash flow from working capital requirements, and regulatory uncertainty around FDA peptide therapy approvals. The stock has gained 49.5% in six months but carries a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.25 | 1 |
| Reasons to Retain Hims & Hers Stock in Your Portfolio for Now | Hims & Hers (HIMS) is accelerating growth through weight loss offerings, international expansion, and AI-enabled care, with U.S. revenues up 16% and international revenues surging 17-fold. However, the company faces headwinds from gross margin compression due to lower-margin branded products, negative cash flow from working capital requirements, and regulatory uncertainty around FDA peptide therapy approvals. The stock has gained 49.5% in six months but carries a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.25 | 1 |
| Should Globus Medical's Expanding Musculoskeletal Pipeline and Cash-Funded Growth Strategy Matter to GMED Investors? - Yahoo Finance | Should Globus Medical's Expanding Musculoskeletal Pipeline and Cash-Funded Growth Strategy Matter to GMED Investors? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| 10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research | 10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies for biomarker discovery in bladder cancer and residual disease detection in acute myeloid leukemia. The company will utilize its Flex Apex and Xenium platforms to identify treatment response markers. Despite the strategic partnership, TXG stock declined 5.6% following the announcement, though it has gained 366.6% year-to-date. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| 10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research | 10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies for biomarker discovery in bladder cancer and residual disease detection in acute myeloid leukemia. The company will utilize its Flex Apex and Xenium platforms to identify treatment response markers. Despite the strategic partnership, TXG stock declined 5.6% following the announcement, though it has gained 366.6% year-to-date. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| 10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research | 10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies for biomarker discovery in bladder cancer and residual disease detection in acute myeloid leukemia. The company will utilize its Flex Apex and Xenium platforms to identify treatment response markers. Despite the strategic partnership, TXG stock declined 5.6% following the announcement, though it has gained 366.6% year-to-date. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Here's Why You Should Retain WAT Stock in Your Portfolio for Now | Waters Corporation (WAT) is positioned for growth driven by sustained analytical sciences demand, BD acquisition integration, and product innovation. The company projects 10.9% year-over-year earnings growth for 2026 with $50 million in revenue synergies and $75 million in cost savings expected. However, weakness in China diagnostics, BD integration execution risks, and dependence on customer capital spending present headwinds. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| Here's Why You Should Retain WAT Stock in Your Portfolio for Now | Waters Corporation (WAT) is positioned for growth driven by sustained analytical sciences demand, BD acquisition integration, and product innovation. The company projects 10.9% year-over-year earnings growth for 2026 with $50 million in revenue synergies and $75 million in cost savings expected. However, weakness in China diagnostics, BD integration execution risks, and dependence on customer capital spending present headwinds. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| Here's Why You Should Retain WAT Stock in Your Portfolio for Now | Waters Corporation (WAT) is positioned for growth driven by sustained analytical sciences demand, BD acquisition integration, and product innovation. The company projects 10.9% year-over-year earnings growth for 2026 with $50 million in revenue synergies and $75 million in cost savings expected. However, weakness in China diagnostics, BD integration execution risks, and dependence on customer capital spending present headwinds. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| Globus Medical (GMED) Stock Sees Modest Fair Value Cut As Analysts Split On Outlook - Yahoo Finance | Globus Medical (GMED) Stock Sees Modest Fair Value Cut As Analysts Split On Outlook Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Globus Medical, Inc. (GMED) Stock Forecasts - Yahoo Finance | Globus Medical, Inc. (GMED) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now | Fresenius Medical Care (FMS) is improving profitability through its FME25+ transformation program and showing promise with 5008X dialysis system adoption and value-based care expansion. However, the company faces significant headwinds including U.S. treatment volume weakness, TDAPA reimbursement reversals expected to create a €50 million headwind in 2026, China regulatory pressure, and inflation concerns. The company maintains a Zacks Rank #3 (Hold) rating with consensus expectations for 2.7% revenue growth but 5.4% earnings decline in 2026. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.75 | 1 |
| BDX Expands U.S. Manufacturing With $19B Healthcare Investment | Becton, Dickinson and Company (BD) announced a landmark partnership with the U.S. Government to invest $19 billion in domestic manufacturing expansion, including $3 billion toward manufacturing capacity. The company aims to increase domestically supplied essential medical consumables to 80% and manufacture all U.S.-used needles domestically with American-made steel. The agreement provides tariff protection on covered products, though financial impact remains unquantified pending finalization of tariff rates and implementation timing. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| BDX Expands U.S. Manufacturing With $19B Healthcare Investment | Becton, Dickinson and Company (BD) announced a landmark partnership with the U.S. Government to invest $19 billion in domestic manufacturing expansion, including $3 billion toward manufacturing capacity. The company aims to increase domestically supplied essential medical consumables to 80% and manufacture all U.S.-used needles domestically with American-made steel. The agreement provides tariff protection on covered products, though financial impact remains unquantified pending finalization of tariff rates and implementation timing. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Reasons to Hold HealthEquity Stock in Your Portfolio for Now | HealthEquity reported solid fiscal Q2 2027 results with revenues up 7.6% and adjusted EPS rising 14.8%. HSA assets reached $37.9 billion with investments growing 20% year-over-year, while AI implementation reduced service costs and improved margins to 48%. The company raised fiscal 2027 adjusted EBITDA guidance to $628-$636 million. However, ongoing cybersecurity litigation and regulatory inquiries from a fiscal 2025 incident pose risks to future growth and profitability. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Reasons to Hold HealthEquity Stock in Your Portfolio for Now | HealthEquity reported solid fiscal Q2 2027 results with revenues up 7.6% and adjusted EPS rising 14.8%. HSA assets reached $37.9 billion with investments growing 20% year-over-year, while AI implementation reduced service costs and improved margins to 48%. The company raised fiscal 2027 adjusted EBITDA guidance to $628-$636 million. However, ongoing cybersecurity litigation and regulatory inquiries from a fiscal 2025 incident pose risks to future growth and profitability. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies | Veeva Systems' Data Quality System (DQS) platform has expanded its reach to support data cleaning across over 1,000 clinical studies involving more than 1 million subjects, generating 500,000+ automated queries. The platform's integration with AI, CTMS, and Study Builder Agent is expected to drive deeper customer engagement and recurring revenue growth in the life sciences software market. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies | Veeva Systems' Data Quality System (DQS) platform has expanded its reach to support data cleaning across over 1,000 clinical studies involving more than 1 million subjects, generating 500,000+ automated queries. The platform's integration with AI, CTMS, and Study Builder Agent is expected to drive deeper customer engagement and recurring revenue growth in the life sciences software market. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Reasons to Add Globus Medical Stock to Your Portfolio Now | Globus Medical (GMED) reported strong Q2 2026 performance with musculoskeletal revenues rising 7.5% and base business sales up 10.9%. The company continues to gain market share through product innovation, with over 60 development projects underway. However, foreign exchange volatility remains a concern. GMED maintains a debt-free balance sheet with $507.7 million in cash, supporting continued R&D and expansion investments. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Charles River Gains 75.8% in a Year: What's Driving the Rally? | Charles River Laboratories (CRL) has outperformed the market with a 75.8% share price increase over the past year, driven by strong Research Models and Services (RMS) prospects and adoption of new approach methodologies. However, the company faces headwinds from uneven demand recovery across client segments, with small and midsized biotech revenues flat and currency fluctuations impacting reported growth. The company maintains a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.75 | 1 |
| Reasons to Add Globus Medical Stock to Your Portfolio Now | Globus Medical (GMED) reported strong Q2 2026 performance with musculoskeletal revenues rising 7.5% and base business sales up 10.9%. The company continues to gain market share through product innovation, with over 60 development projects underway. However, foreign exchange volatility remains a concern. GMED maintains a debt-free balance sheet with $507.7 million in cash, supporting continued R&D and expansion investments. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Charles River Gains 75.8% in a Year: What's Driving the Rally? | Charles River Laboratories (CRL) has outperformed the market with a 75.8% share price increase over the past year, driven by strong Research Models and Services (RMS) prospects and adoption of new approach methodologies. However, the company faces headwinds from uneven demand recovery across client segments, with small and midsized biotech revenues flat and currency fluctuations impacting reported growth. The company maintains a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.75 | 1 |
| Reasons to Add Globus Medical Stock to Your Portfolio Now - TradingView | Reasons to Add Globus Medical Stock to Your Portfolio Now TradingView | View source ↗ | TradingView | Oct 7, 2026 | neutral | 0 | 0.6 |
| Is This the Right Time to Add TMO Stock to Your Portfolio? | Thermo Fisher Scientific (TMO) is strengthening growth through innovation, AI investments, and strategic acquisitions expected to contribute $1.6 billion in revenues and 32 cents to adjusted EPS in 2026. The company expects organic revenue growth at 3%-4% for 2026 supported by broad-based end-market improvements. However, risks from macroeconomic uncertainty, inflation, geopolitical disruption, and unfavorable currency movements could weigh on results and margins. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Is This the Right Time to Add TMO Stock to Your Portfolio? | Thermo Fisher Scientific (TMO) is strengthening growth through innovation, AI investments, and strategic acquisitions expected to contribute $1.6 billion in revenues and 32 cents to adjusted EPS in 2026. The company expects organic revenue growth at 3%-4% for 2026 supported by broad-based end-market improvements. However, risks from macroeconomic uncertainty, inflation, geopolitical disruption, and unfavorable currency movements could weigh on results and margins. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Is It Prudent to Add Teleflex Stock to Your Portfolio Now? | Teleflex (TFX) reported Q2 2026 Vascular revenue growth of 9% driven by central access and hemostatic product demand, with Asia revenues jumping 59.5%. However, tariffs and acquisition costs pressured margins, with adjusted operating margin declining 520 basis points. The company improved its balance sheet with pro forma net leverage at 1.9X after debt repayment. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.75 | 1 |
| Is It Prudent to Add Teleflex Stock to Your Portfolio Now? | Teleflex (TFX) reported Q2 2026 Vascular revenue growth of 9% driven by central access and hemostatic product demand, with Asia revenues jumping 59.5%. However, tariffs and acquisition costs pressured margins, with adjusted operating margin declining 520 basis points. The company improved its balance sheet with pro forma net leverage at 1.9X after debt repayment. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.75 | 1 |
| Reasons to Retain Cardinal Health Stock in Your Portfolio for Now | Cardinal Health (CAH) expects Pharma profit growth of 8-11% in fiscal 2027 despite normalized demand, with other businesses projected to grow 15-18%. The company benefits from strong operational efficiency and specialty pharmaceutical growth, but faces headwinds from IRA pricing changes, moderating Specialty growth, and commodity cost pressures in its GMPD segment. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.75 | 1 |
| Reasons to Retain Cardinal Health Stock in Your Portfolio for Now | Cardinal Health (CAH) expects Pharma profit growth of 8-11% in fiscal 2027 despite normalized demand, with other businesses projected to grow 15-18%. The company benefits from strong operational efficiency and specialty pharmaceutical growth, but faces headwinds from IRA pricing changes, moderating Specialty growth, and commodity cost pressures in its GMPD segment. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.75 | 1 |
| Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific | The Medical Instruments industry is experiencing growth driven by generative AI adoption, with the AI-enabled medical devices market projected to expand at 19.9% CAGR through 2034. The industry carries a Zacks Industry Rank #86 (top 35%), though it has underperformed the S&P 500 and broader sector over the past year. Three stocks highlighted for potential outperformance are Globus Medical (Rank #1), Intuitive Surgical (Rank #2), and Thermo Fisher Scientific (Rank #2), all benefiting from AI integration, M&A activity, and strong earnings growth projections. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 1 | 1 |
| Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific | The Medical Instruments industry is experiencing growth driven by generative AI adoption, with the AI-enabled medical devices market projected to expand at 19.9% CAGR through 2034. The industry carries a Zacks Industry Rank #86 (top 35%), though it has underperformed the S&P 500 and broader sector over the past year. Three stocks highlighted for potential outperformance are Globus Medical (Rank #1), Intuitive Surgical (Rank #2), and Thermo Fisher Scientific (Rank #2), all benefiting from AI integration, M&A activity, and strong earnings growth projections. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 1 | 1 |
| Reasons to Retain Doximity Stock in Your Portfolio for Now | Doximity (DOCS) is experiencing strong clinical AI adoption with active workflow prescribers up 30% year-over-year and AI Scribe users growing 10-fold, validating its AI capabilities through independent studies. However, the company faces headwinds from modest overall revenue growth (7% YoY), declining gross margins (88% from 91%) due to elevated AI infrastructure costs, and a constrained pharma advertising market. While AI is opening new revenue opportunities, investors await evidence that AI monetization can materially accelerate consolidated growth. | View source ↗ | Zacks Investment Research | Oct 5, 2026 | bullish | 0.75 | 1 |
| Here's Why Globus Medical (GMED) is a Strong Value Stock | Zacks presents its investment research tools including Thematic Investment Screens covering 37 themes and the Zacks Rank stock-rating system combined with Style Scores (Value, Growth, Momentum, VGM). The article highlights how the Zacks Rank #1 stocks have averaged +23.86% annual returns since 1988, outperforming the S&P 500. Globus Medical (GMED) is featured as a #1 Strong Buy with attractive valuation metrics. | View source ↗ | Zacks Investment Research | Oct 5, 2026 | bullish | 1 | 1 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.